LABCORP HOLDINGS INC. 10-K

Item 2. PROPERTIES The Company’s corporate headquarters are located in Burlington, North Carolina, and include facilities that are both owned and leased. Dx operates through a network of PSCs, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The table below summarizes certain information as to Dx’s principal operating and administrative facilities at December 31, 2025. Location Nature of Occupancy Birmingham, Alabama Leased Phoenix, Arizona Owned Los Angeles, California Leased Monrovia, California Leased San Diego, California Leased San Francisco, California (2) Leased Shelton, Connecticut Leased Tampa, Florida Leased South Bend, Indiana Leased Wichita, Kansas Leased Baltimore, Maryland Leased Holyoke, Massachusetts Leased Westborough, Massachusetts Leased Troy, Michigan Leased St. Paul, Minnesota Owned Raritan, New Jersey Owned Burlington, North Carolina (5) Owned/Leased Research Triangle Park, North Carolina (3) Leased Dublin, Ohio Owned Tulsa, Oklahoma Leased Brentwood, Tennessee Leased Dallas, Texas Leased Houston, Texas Leased Herndon, Virginia Leased Seattle, Washington Leased Spokane, Washington Leased Oak Creek, Wisconsin Leased 34 TABLE OF CONTENTS BLS operates globally. The table below summarizes certain information as to BLS’s principal operating and administrative facilities at December 31, 2025. Location Nature of Occupancy Mechelen, Belgium Leased Shanghai, China (2) Leased/Owned Munster, Germany Owned Bangalore, India Leased Singapore Leased Geneva, Switzerland (2) Owned/Leased Eye, United Kingdom Owned Harrogate, United Kingdom Owned Huntingdon, United Kingdom Owned Shardlow, United Kingdom Owned York, United Kingdom Leased Greenfield, Indiana Owned Indianapolis, Indiana Leased Bedford, Massachusetts Owned Ann Arbor, Michigan Leased Somerset, New Jersey Owned Denver, Pennsylvania Leased Chantilly, Virginia Leased Madison, Wisconsin Owned All of the Company’s primary facilities have been built or improved for the purpose of providing commercial laboratory testing or biopharma laboratory services. The Company believes that these existing facilities and plans for expansion are suitable and adequate and will provide sufficient production capacity for the Company’s currently foreseeable level of operations. The Company believes that if it were unable to renew a lease or if a lease were to be terminated on any of the facilities it presently leases, it could find alternate space at competitive market rates and readily relocate its operations to such new location without material disruption to its operations. Item 3. LEGAL PROCEEDINGS See Note 15 Commitments and Contingencies to the Consolidated Financial Statements. Item 4. MINE SAFETY DISCLOSURES Not applicable. 35 TABLE OF CONTENTS PART II